Skip to main content

Table 1 Baseline characteristics of patients

From: A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study

Characteristics Training(n = 229) Validation(n = 107)
Age (years)
  < 60 192(83.8%) 85(79.4%)
  ≥ 60 37(16.2%) 22(20.6%)
Gender
 Male 153(66.8%) 72(67.3%)
 Female 76(33.2%) 35(32.7%)
ECOG score
  < 2 168(73.4%) 75(70.1%)
  ≥ 2 61(26.6%) 32(29.9%)
Ann Arbor stages
 I–II 97(42.4%) 50(46.7%)
 III–IV 132(57.6%) 57(53.3%)
B symptoms 57(24.9%) 22(20.6%)
Risk stratification
 Low 76(33.2%) 41(38.3%)
 High 153(66.8%) 66(61.7%)
Bone marrow involved 36(15.7%) 16(15%)
Central nervous system (CNS) involved 14(6.1%) 5(4.7%)
Lymph-node involvement 111(48.5%) 49(45.8%)
Extranodal involvement sites
  < 2 122(53.3%) 63(58.9%)
  ≥ 2 107(46.7%) 44(41.1%)
EBV encoded small RNAs (EBERs)(+) 48(21%) 28(26.2%)
ALB < 40 mg/L 92(40.2%) 58(54.2%)
CRP ≥ 10 mg/L 101(43.7%) 47(43.9%)
LDH ≥ 334 U/L 87(38%) 43(40.2%)
d-NLR ≥ 1.6 58(25.3%) 34(31.8%)
PLT < 254 × 109/L 127(55.5%) 54(50.5%)
International Prognostic Indexs (IPI) score ≥ 2 137(59.8%) 61(57%)
Radiation therapy 29(12.7%) 12(11.2%)
ASCT 9(3.9%) 3(2.8%)
CNS prophylaxis 184(80.3%) 89(83.2%)
Abdominal lesions 137(59.8%) 58(54.2%)
Chemotherapy regimen
 R-CODOX-M 152(66.4%) 69(64.5%)
 R-EPOCH 25(10.9%) 8(7.5%)
 R-CHOP 28(12.2%) 15(14%)
 R-Hyper-CVAD 17(7.4%) 12(11.2%)
 Others 7(3.1%) 3(2.8%)